for those with her2+ bc brain mets, herceptin+lapatinib increases median overall surv
vival more than 2.5 times compared to either anti her2 agent alone!!!!
The Breast
Volume 22, Issue 5, October 2013, Pages 993–998
Cover image
Original article
Prognostic factors of brain metastases from breast cancer: Impact of targeted therapies
Antoine Laurent Braccinia, Corresponding author contact information, E-mail the corresponding author,
David Azriaa,
Simon Thezenasb,
Gilles Romieuc,
Jean Marc Ferrerod,
William Jacotc
a Department of Radiation Oncology, Val d'Aurelle Cancer Institute, 208 rue des Apothicaires, 34298 Montpellier, France
b Department of Biostatistics, Val d'Aurelle Cancer Institute, 208 rue des Apothicaires, 34298 Montpellier, France
c Department of Medical Oncology, Val d'Aurelle Cancer Institute, 208 rue des Apothicaires, 34298 Montpellier, France
d Department of Medical Oncology, Antoine Lacassagne Cancer Institute, 33 Avenue de Valombrose, 06189 Nice Cedex 02, France
Abstract
Introduction
Brain metastases (BM) from breast cancer are associated with poor prognosis. This study was made to determine the prognostic influence of breast cancer biological subtypes, and to define the best therapeutic options in this setting, with a special focus on the HER2-positive population.
Patients and methods
Breast cancer patients with known hormone receptors (HR) and HER2 status presenting with BM treated between 1995 and 2010 in our two institutions were considered for this retrospective study.
Results
250 patients were included. The study population consisted of 25.6% patients categorized as triple-negative (HR−/HER2−), 30.8% as HR+/HER2− and 43.6% as HER2+ breast cancer. Median overall survival (OS) was 8.9 months (95% CI, 6.9–10.3 months). Cerebral progression remained the most frequent cause of death (57.1%). On multivariate analysis, HER2 positivity and the RPA score were the two most important prognostic factors. Local treatment (surgery or stereotactic radiotherapy) and chemotherapy were significantly associated with an increased survival. On multivariate analysis of the RPA1-2 population, local treatment and chemotherapy were independent prognostic factors in addition to biological subtypes, RPA class, liver metastases and clinical signs of intra-cranial hypertension. Anti-HER2 therapies administered after BM diagnosis significantly and independently increased OS. Median OS in patients receiving both trastuzumab and lapatinib after BM diagnosis was significantly better than that the one of patients receiving only one of the 2 targeted therapies (25.7 vs. 9.6 months, p < 0.001).
Conclusions
Biological subtypes are independent prognostic determinants. Chemotherapy and targeted therapies positively affect the prognosis after first BM.
|
Linear Mode
